DexCom, Inc. (DXCM) Income Statement

The sequential acceleration from 2.0% in 2024Q3 to 13.1% in 2026Q2 suggests the company is capturing a broader Type 2 patient population, likely aided by the CMS coverage expansion. This growth appears durable as the pharmacy channel lowers access barriers, though it may come with lower realized pricing per unit. Investors should monitor whether this pace can be sustained as the base of covered patients matures.

The 640 basis point improvement in gross margin over five quarters indicates that manufacturing efficiencies from the G7 ramp are materializing, offsetting the dilutive effect of the pharmacy channel. This suggests the company has successfully managed the transition to lower-margin channels while improving production costs. However, the sustainability of this margin level depends on maintaining yield rates and managing competitive pricing pressures from Abbott's Libre 3.

The 1,330 basis point expansion in operating margin over the period demonstrates significant operating leverage, with SG&A growing only 12% year-over-year in 2026Q2 versus revenue growth of 13.1%. This suggests the company is scaling its infrastructure efficiently, likely benefiting from prior investments in automation and a growing revenue base. The trend indicates that incremental revenue is flowing to the bottom line at an increasing rate, though competitive dynamics could pressure this if marketing spend needs to rise.

The stability of R&D spending as a percentage of revenue (declining from 15.4% in 2024Q1 to 11.7% in 2026Q2) suggests the company is leveraging its existing technology platform while still investing in next-generation products. This discipline supports margin expansion, but investors should watch for potential increases in R&D if the company pursues new indications or data-driven initiatives. The cost structure appears well-controlled, with COGS and SG&A scaling appropriately with revenue.